| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Third Division of the Research Laboratory for Development of Medicine, School of Pharmacy, Hokuriku University, Ho-3 Kanagawa-machi, Kanazawa 920-11, Japan
Adenylate cyclase activation through adrenergic receptors in rat ascites hepatoma (AH) 130 cells in response to adrenergic drugs was studied, and receptor binding and displacement were compared with those of normal rat hepatocytes. Epinephrine (Epi) and norepinephrine (NE) activated AH130 adenylate cyclase about half as much as isoproterenol (IPN) but equaled IPN after treatment with the
-antagonist phentolamine or islet-activating protein (IAP). The three catecholamines in hepatocytes were similar regardless of phentolamine or IAP. These catecholamines activated adenylate cyclase in order of IPN > NE > Epi in AH130 cells but IPN > Epi > NE in hepatocytes. We then used the
1-selective ligand [3H]prazosin, the
2-selective ligand [3H]clonidine, and the ß-ligand [125I]iodocyanopindolol ([125I]ICYP), and found that AH130 cells had few prazosin-binding sites, about eight times as many clonidine-binding sites with high affinity, and many more ICYP-binding sites than in hepatocytes. The dissociation constant (Ki) of the ß1-selective drug metoprolol by Hofstee plots for AH130 cells was lower than that for hepatocytes. The inhibition of specific ICYP binding by the ß2-selective agonist salbutamol for AH130 cells gave only one Ki value which was much higher than both high and low Ki values of the drug for hepatocytes. These findings indicate that the
- and ß-adrenergic receptors in hepatocytes are predominantly
1- type and ß2-type, but that those in AH130 cells are predominantly
2-type and ß1-type, and the low adrenergic response of AH130 cells is due to the dominant appearance of
2-adrenergic receptors, linked with the inhibitory guanine-nucleotide binding regulatory protein, instead of
1-adrenergic receptors, and ß1-adrenergic receptors with low affinity for the hormone.
1 To whom requests for reprints should be addressed.
Received 4/20/89. Revised 7/13/89. Accepted 8/17/89.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |